AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00560690 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: 800-1200 mg PO given in 2 divided doses for 6 to 12 months depending on weight and genotype
Study NCT01334502 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: PO
Study NCT01334502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: IV
Study NCT01334502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: IV
Study NCT01334502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: PO
Study NCT01334502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: PO
Study NCT01334502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: IV
Study NCT01061398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac CT Angiography
Description: Patients randomized to CT Arm will undergo 64-slice cardiac CT angiography (single scan) in addition to the stress imaging test ordered by their physician
Study NCT01061398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stress Imaging Test (Stress Myocardial Perfusion Study or Stress Echocardiogram)
Description: Stress imaging test as ordered by the subjects provider without option for cardiac CT angiography (no CT arm)
Study NCT02078557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8892
Study NCT00836407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab (10mg/kg) will be administered intravenously at weeks 1, 4, 7 and 10. Subjects will also be offered maintenance phase dosing every 12 weeks.
Study NCT00836407 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pancreatic Cancer Vaccine
Description: The Pancreatic Cancer Vaccine (5E8 cells) will be administered intradermally at weeks 1, 4, 7 and 10. Subjects will also be offered maintenance phase dosing every 12 weeks.
Study NCT05579028 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Nutridrink ONS 200 ml
Description: Nutridrink is a high-protein, high-calorie formula for the specialized nutrition of patients with or at risk of malnutrition. The product can be used as an additional or sole source of nutrition
Study NCT01257178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624803
Description: Administered orally
Study NCT03635541 — intervention group
Intervention type: OTHER
Intervention: observational group of NAFLD
Description: there's no intervention for patients for it is a observational study
Study NCT02319018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO
Study NCT02319018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT02319018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02319018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT02319018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT02760680 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WatchPAT 200 (TM)
Description: The WatchPAT 200 (TM) is a wrist worn diagnostic device for detecting SDB. Its main part is the measurement of the peripheral arterial tone (PAT) via a plethysmographic based finger-mounted probe. It can measure the level of sympathetic activation of the autonomic nervous system. Pulse rate, oxygen saturation and snoring/body position levels are calculated, too. A software program (zzzPAT (TM)) with a special algorithm analyzes the raw data and creates a sleep report. Therefore the property of the WatchPAT 200 (TM) proclaims that the WatchPAT 200 (TM) can detect sleep events and SDB.
Study NCT02760680 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: WatchPAT 200 (TM)
Description: The WatchPAT 200 (TM) is a wrist worn diagnostic device for detecting SDB. Its main part is the measurement of the peripheral arterial tone (PAT) via a plethysmographic based finger-mounted probe. It can measure the level of sympathetic activation of the autonomic nervous system. Pulse rate, oxygen saturation and snoring/body position levels are calculated, too. A software program (zzzPAT (TM)) with a special algorithm analyzes the raw data and creates a sleep report. Therefore the property of the WatchPAT 200 (TM) proclaims that the WatchPAT 200 (TM) can detect sleep events and SDB.
Study NCT02760680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Polysomnography
Description: The PSG is known as the Gold Standard for detecting SDB: experienced sleep physicians and technicians score events (apnea/hypopnea) using current AASM Guidelines.
Study NCT02760680 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Polysomnography
Description: The PSG is known as the Gold Standard for detecting SDB: experienced sleep physicians and technicians score events (apnea/hypopnea) using current AASM Guidelines.
Study NCT03717220 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: flap transferring
Description: we use regional dorsal digital flaps for simultaneous reconstruction of multiple-digit soft-tissue defects
Study NCT00731094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expert system-based physical activity counseling
Description: The intervention included 14 mailings to participants that involved completion of physical activity questionnaires printed on forms that were scanned into a computerized expert system program to generate individually-tailored feedback messages and related manuals based on the Stages of Motivational Readiness for Change Model. Newsletters providing additional support and suggestions for increasing physical activity were also part of the mailing program.
Study NCT00462501 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00462501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00462501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00462501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT00462501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00462501 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT04427423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy treatment
Description: the experimental group received positional distraction plus stabilization exercises and the control group received stabilization exercises only.
Study NCT04427423 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy treatment
Description: the experimental group received positional distraction plus stabilization exercises and the control group received stabilization exercises only.
Study NCT00556972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fecal Incontinence Management System
Description: The device is intended to remedy fecal incontinence.
Study NCT02620826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect pulp therapy
Description: Decayed dentin is lined with a resin-modified glass ionomer (Vitrebond Plus)
Study NCT02620826 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomy
Description: A cervical pulpotomy is done and the radicular pulp is lined with Mineral Trioxide Aggregate
Study NCT03004898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multidisciplinary renal education
Description: multidisciplinary CKD care involving case management nurse, dietitian, social worker, pharmacists.
Study NCT01970020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168
Description: Following an at least 10-hour overnight fast, participants will receive a single dose containing 30 mg of 14C JNJ-38518168 given as an oral solution on Day 1
Study NCT00938366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Subjects will receive two single doses of 10 mg cladribine orally in either first or second intervention period followed by a washout period of 10-25 days.
Study NCT00938366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Subjects will receive a pantoprazole 40 mg orally for 2 consecutive days either in first or second intervention period.
Study NCT04516109 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified hip capsule side fixed slotted cannula
Description: Modified hip capsule side fixed slotted cannula used during surgery to allow for continued access to the hip joint.
Study NCT04516109 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified bone graft delivery tool set
Description: Modified bone graft delivery tool set for grafting subchrondral cysts arthroscopically during hip arthroscopy procedure.
Study NCT04789876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphate mobile app
Description: The phosphate mobile app has the features of i) matching phosphate binder with dietary phosphate intake, ii) educational videos of phosphate management, iii) food database with local food items, iv) record-keeping and goal setting.
Study NCT04789876 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One-off dietary counselling with a phosphate booklet
Description: One-off 45-minute dietary counselling delivered by a dietitian at the baseline of the study. Patients received a complimentary phosphate booklet after the counselling session. The phosphate booklet contains similar educational information as per the phosphate mobile app excluding the matching of phosphate binder with dietary phosphate information.
Study NCT01685697 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mask ventilation with a Laerdal face mask
Description: Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the intervention group.
Study NCT01685697 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mask ventilation with a F&P face mask
Description: Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the control group.
Study NCT01461707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone-based physical activity
Description: Participants will receive the mobile phone-based physical activity program using the trial app.
Study NCT01461707 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activity monitor
Description: Participants will receive an activity monitor
Study NCT01461707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity monitor
Description: Participants will receive an activity monitor
Study NCT04459871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant human Thrombin(CHO cell)
Description: 2 rhThrombin, dissolved in 5mL sterile saline and mixed, the final solution contains 1000IU/mL rhThrombin solution (clear and transparent liquid).
Study NCT04459871 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, dissolved in 5mL sterile saline and mixed, the final solution contains 1000IU/mL rhThrombin solution (clear and transparent liquid).
Study NCT00535002 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Yohimbine
Description: Participants were pre-treated with either yohimbine or placebo.
Study NCT00535002 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study NCT00607282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Udenafil
Description: oral administration of Udenafil, prn(2hours before anticipated intercourse, 8 times/months)
Study NCT00607282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: oral administration of Udenafil, prn(2hours before anticipated intercourse, 8 times/months)
Study NCT04022135 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid
Description: Participants will supplement with 0.6mg/day for 16 weeks.
Study NCT04022135 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: (6S)-5-methyltetrahydrofolic acid
Description: Participants will supplement with 0.625mg/day for 16 weeks.
Study NCT02850003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-120 Gel
Description: Gel
Study NCT04566237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Objective Scatter Index (OSI)
Description: On Optical Quality Analysis System (OQAS) device. At Inclusion, 3 months, 12 months and 24 months after vitrectomy
Study NCT04566237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Average Lens Density (ALD)
Description: on IOLMaster® 700 device. At Inclusion, 3 months, 12 months and 24 months after vitrectomy
Study NCT04052542 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional online continuing education
Description: 30-minute, online, interactive, educational video describing the benefits of preventive post-extubation NIV, the indications and contraindications for preventive post-extubation NIV, and the value of working together as an interprofessional ICU team when implementing preventive post-extubation NIV
Study NCT04052542 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interprofessional education
Description: One-time, 90-120-minute, in-person, interprofessional educational workshop consisting of a 30-minute didactic session and a 60-90-minute small group session
Study NCT04052542 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Just-in-time education
Description: Just-in-time, point-of-care education provided by trained advanced practice providers who will be on-hand in the study ICU, where they will deliver the education at the bedside during rounds when a patient meets criteria for preventive post-extubation NIV
Study NCT02989753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VAL070-A
Description: After randomization (V1 visit), 8 capsules per day of VAL070-A during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
Study NCT02989753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VAL070-B
Description: After randomization (V1 visit), 8 capsules per day of VAL070-B during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
Study NCT02989753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After randomization (V1 visit), 8 capsules per day of placebo during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
Study NCT03798327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Palliative Care
Description: Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
Study NCT01339390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVE OUT
Description: The MOVE OUT intervention builds on the high quality information provided by the nationally-developed MOVE program by adding 1) peer support; 2) convenient local access to educational sessions, which allows the material to be delivered in smaller, more easily retained aliquots; 3) convenient local exercise opportunities; and 4) open-ended availability of both education and exercise support.
Study NCT01339390 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MOVE!
Description: As part of routine care at the ZVAMC, all patients who are eligible for the present study are identified by a clinical reminder. This reminder prompts the PCP to determine if the person would benefit from a weight loss program, and to refer them to MOVE if they and the patient agree that it would be beneficial. The MOVE program in Milwaukee can be tailored by the patient and PCP, but includes dietitian assessment, education, weekly weigh-ins, follow-up classes, and exercise programs.
Study NCT01062529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Description: 4 h of 150 microgram infusion
Study NCT03445936 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parietene Macro
Description: Parietene Macro is placed and sutured on retro muscular space on closed posterior rectus sheath to prevent incisional hernia.
Study NCT03445936 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Permacol
Description: Permacol biologic implant is placed and sutured on retro muscular space on closed posterior rectus sheath to prevent incisional hernia.
Study NCT00509223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure therapy
Description: Positive Airway Pressure (PAP) therapy initiated at Randomization and continued through the entire study duration (6 months), with instructions for use on a daily basis, during periods of sleep.
Study NCT00509223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Lifestyle counseling: All subjects were counseled regarding adopting a healthy lifestyle and advised on the Heart Foundation, National Health and Medical Research Council, and American Diabetes Association nutrition and exercise recommendations.
Study NCT00509223 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: Lifestyle counseling: All subjects were counseled regarding adopting a healthy lifestyle and advised on the Heart Foundation, National Health and Medical Research Council, and American Diabetes Association nutrition and exercise recommendations.
Study NCT02007824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ULSD-12D
Description: wound cleansing and debridement using ULSD-12D
Study NCT02007824 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SONOCA-180
Description: wound cleansing and debridement using SONOCA-180
Study NCT03678909 — intervention group
Intervention type: PROCEDURE
Intervention: Norwood Palliation / DKS / Damus-Kaye-Stansel procedure
Description: Norwood Palliation / DKS / Damus-Kaye-Stansel procedure
Study NCT01821131 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: muffin
Study NCT01821131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: muffin
Study NCT03803371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultracet Tablets
Description: Ultracet tablet (Janssen Cilag Farmacêutica Ltda) equivalent to Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg
Study NCT03803371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets - tablet (Pfizer)
Description: Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets (Pfizer)
Study NCT03329404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirasol Red Blood Cells (MIR RBCs)
Description: Mirasol Red Blood Cells (MIR RBCs) derived from Mirasol-treated WB; WB will be Mirasol treated, centfifuged and leukoreduced and the derived RBCs will be stored before transfusion for up to 21 days and transfused according to the patient's transfusion schedule.
Study NCT03329404 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reference Red Blood Cells (REF RBCs)
Description: Reference Red Blood Cells (REF RBCs) will be acquired from routine use inventory and transfused according to the patient's transfusion schedule.
Study NCT01959282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo once daily
Study NCT01959282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54781532 25 mg once daily
Description: Participants will receive 25 mg of JNJ-54781532 once daily
Study NCT01959282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54781532 75 mg once daily
Description: Participants will receive 75 mg of JNJ-54781532 once daily
Study NCT01959282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54781532 150 mg once daily
Description: Participants will receive 150 mg of JNJ-54781532 once daily
Study NCT01959282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JNJ-54781532 150 mg once daily
Description: Participants will receive 150 mg of JNJ-54781532 once daily
Study NCT01959282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54781532 75 mg twice daily
Description: Participants will receive 75 mg of JNJ-54781532 twice daily
Study NCT02525367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online cognitive training
Description: The intervention is a computerized, online training programme which aims to train several cognitive abilities; especially the executive functions, attention, working memory and processing speed. The mental processes that are appealed to by the intervention are similar to processes that are trained in classic face-to-face training methods. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.